within Pharmacolibrary.Drugs.ATC.R;

model R01AC03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.4,
    Cl             = 0.008333333333333333,
    adminDuration  = 600,
    adminMass      = 0.0005600000000000001,
    adminCount     = 1,
    Vd             = 0.0145,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Azelastine is a second-generation antihistamine used primarily as a nasal spray or eye drop for the symptomatic treatment of allergic rhinitis and allergic conjunctivitis. It works by selectively antagonizing histamine H1 receptors, thereby reducing allergy symptoms. Azelastine is approved and in clinical use today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after intranasal administration.</p><h4>References</h4><ol><li><p>Ridolo, E, et al., &amp; Canonica, GW (2015). A role for the intranasal formulation of azelastine hydrochloride/fluticasone propionate in the treatment of allergic rhinitis. <i>Therapeutic delivery</i> 6(6) 653–659. DOI:<a href=&quot;https://doi.org/10.4155/tde.15.7&quot;>10.4155/tde.15.7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25913181/&quot;>https://pubmed.ncbi.nlm.nih.gov/25913181</a></p></li><li><p>Bernstein, JA (2007). Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability. <i>Current medical research and opinion</i> 23(10) 2441–2452. DOI:<a href=&quot;https://doi.org/10.1185/030079907X226302&quot;>10.1185/030079907X226302</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17723160/&quot;>https://pubmed.ncbi.nlm.nih.gov/17723160</a></p></li><li><p>Klimek, L, et al., &amp; Price, D (2016). Safety evaluation of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) for allergic rhinitis. <i>Expert opinion on drug safety</i> 15(1) 117–129. DOI:<a href=&quot;https://doi.org/10.1517/14740338.2016.1122755&quot;>10.1517/14740338.2016.1122755</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26581312/&quot;>https://pubmed.ncbi.nlm.nih.gov/26581312</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R01AC03;
